Select for export [Treatment-resistant depression. From classification to new therapies.] Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1708/3922.39072 PubMed 36503940 Copy citation Copy BibTeX Rivista di psichiatria 2022-10-31 Paganin W, Signorini S, Leccese V, Sciarretta A. Europe PMC Published psilocybin DepressionAgingTreatment-Resistant Depression Other More
Select for export Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1056/nejmoa2206443 PubMed 36322843 Copy citation Copy BibTeX New England Journal of Medicine 2022-10-31 Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC Europe PMC Published psilocybin DepressionClinical TrialTreatment-Resistant Depression Clinical Trial More
Select for export Psilocybin in Treatment-Resistant Depression. No abstract availability was recorded for this entry. Details DOI 10.1056/nejme2210975 PubMed 36322849 Copy citation Copy BibTeX Unknown journal 2022-10-31 Madras BK. Europe PMC Published psilocybin DepressionTreatment-Resistant Depression Other More
Select for export Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1177/02698811221127304 PubMed 36314881 Copy citation Copy BibTeX Journal of Psychopharmacology 2022-10-30 Jones GM. Europe PMC Published psilocybin DepressionObservational StudyDrug Interactions Observational Study More
Select for export A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1089/psymed.2022.0002 PubMed 37337526 Copy citation Copy BibTeX Psychedelic Medicine 2022-10-27 Nayak SM, Bari BA, Yaden DB, Spriggs MJ, Rosas FE, Peill JM Europe PMC Published psilocybin Depression Other More
Select for export The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. Abstract available at the source but not redistributed here. Read at source. Details Copy citation Copy BibTeX ClinicalTrials.gov 2022-10-24 Sheppard Pratt Health System ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionSafety Other More
Select for export Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1016/j.jad.2022.09.168 PubMed 36209780 Copy citation Copy BibTeX Unknown journal 2022-10-06 Ko K, Kopra EI, Cleare AJ, Rucker JJ. Europe PMC Published psilocybin DepressionEnd-of-Life DistressClinical Trial Randomized Controlled Trial More
Select for export A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1097/jcp.0000000000001608 PubMed 36193898 Copy citation Copy BibTeX Unknown journal 2022-10-02 Ledwos N, Rosenblat JD, Blumberger DM, Castle DJ, McIntyre RS, Mulsant BH Europe PMC Published psilocybin DepressionEnd-of-Life DistressReceptor Pharmacology Randomized Controlled Trial More
Select for export 19.3 Psilocybin-Assisted Therapy for MDD: Current Evidence and Clinical Considerations No abstract availability was recorded for this entry. Details DOI 10.1016/j.jaac.2022.07.664 Copy citation Copy BibTeX Journal of the American Academy of Child & Adolescent Psychiatry 2022-09-30 Natalie Gukasyan OpenAlex Published psilocybin DepressionAnxietyReceptor Pharmacology Randomized Controlled Trial More
Select for export New investigational agents for the treatment of major depressive disorder. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1080/13543784.2022.2113376 PubMed 35975761 Copy citation Copy BibTeX Expert opinion on investigational drugs 2022-09-30 Pochwat B, Krupa AJ, Siwek M, Szewczyk B PubMed Published psilocybin DepressionMechanism of ActionReceptor Pharmacology Review Article More
Select for export Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.3390/ijms231911450 PubMed 36232748 Copy citation Copy BibTeX Unknown journal 2022-09-27 Psiuk D, Nowak EM, Dycha N, Łopuszańska U, Kurzepa J, Samardakiewicz M. Europe PMC Published psilocybin DepressionSystematic ReviewReview Article Systematic Review More
Select for export Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1192/bjo.2022.565 PubMed 36065128 Copy citation Copy BibTeX BJPsych Open 2022-09-05 Barba T, Buehler S, Kettner H, Radu C, Cunha BG, Nutt DJ Europe PMC Published psilocybin DepressionMechanism of ActionReceptor Pharmacology Clinical Trial More
Select for export Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop Abstract available at the source but not redistributed here. Read at source. Details PubMed 36049038 Copy citation Copy BibTeX National Academies Press (US), Washington (DC) 2022-08-31 National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Neuroscience and Nervous System Disorders. Europe PMC Published psilocybin DepressionAnxietyPTSD Other More
Select for export [The use of psilocybin for treatment-resistant depression]. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.17992/lbl.2022.09.706 PubMed 36040772 Copy citation Copy BibTeX Unknown journal 2022-08-31 Johannesdottir A, Sigurdsson E. Europe PMC Published psilocybin DepressionHeadache / MigraineMechanism of Action Randomized Controlled Trial More
Select for export The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.7759/cureus.29167 PubMed 36259015 Copy citation Copy BibTeX Cureus 2022-08-31 Kurtz JS, Patel NA, Gendreau JL, Yang C, Brown N, Bui N PubMed Published psilocybin DepressionPTSDAddiction Clinical Trial More
Select for export Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1080/17460441.2022.2111415 PubMed 35934973 Copy citation Copy BibTeX Expert Opinion on Drug Discovery 2022-08-21 Pilc A, Machaczka A, Kawalec P, Smith JL, Witkin JM. Europe PMC Published psilocybin DepressionPharmacologyMechanism of Action Animal Study More
Select for export The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1177/07067437221111371 PubMed 35975555 Copy citation Copy BibTeX Unknown journal 2022-08-16 Rosenblat JD, Husain MI, Lee Y, McIntyre RS, Mansur RB, Castle D Europe PMC Published psilocybin DepressionAnxietyHeadache / Migraine Randomized Controlled Trial More
Select for export Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1007/s11920-022-01361-0 PubMed 35953638 Copy citation Copy BibTeX Unknown journal 2022-08-11 Prouzeau D, Conejero I, Voyvodic PL, Becamel C, Abbar M, Lopez-Castroman J. Europe PMC Published psilocybin DepressionEnd-of-Life DistressMechanism of Action Clinical Trial More
Select for export The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1007/s00213-022-06187-5 PubMed 35939083 Copy citation Copy BibTeX Psychopharmacology 2022-08-07 Watts R, Kettner H, Geerts D, Gandy S, Kartner L, Mertens L Europe PMC Published psilocybin DepressionEmotional ProcessingClinical Trial Randomized Controlled Trial More
Select for export Med Check: Psilocybin for OCD, Nuplazid Vote, and More Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1176/appi.pn.2022.08.8.2 Copy citation Copy BibTeX Psychiatric News 2022-07-31 Terri D’Arrigo OpenAlex Published psilocybin DepressionOCDHeadache / Migraine Clinical Trial More
Psilocybin-Research.com
Searchable psilocybin and psilocin bibliometric database.